IDO, Human, pAb
The polyclonal antibody recognizes human indoleamine 2,3-dioxygenase (IDO). IDO is an intracellular heme-containing enzyme that catalyzes the oxidative cleavage of the indole ring of several important regulatory molecules, like tryptophan, serotonin and melatonin. By doing this, IDO initiates the production of biologically active metabolites, commonly referred to as kynurenines. IDO is widely expressed in a variety of human tissues as well as in macrophages and dendritic cells (DCs). In inflammation, interferons (IFNs) act on specific receptors to trigger IDO induction. The production of IFN-gamma and induction of IDO represent important antimicrobial mechanisms. Degradation and depletion of tryptophan by IDO inhibits the growth of viruses, bacteria and parasites. Furthermore, IDO plays a complex and crucial role in immunoregulation during infection, pregnancy, autoimmunity, transplantation, and neoplasia. By local depletion of tryptophan and increasing proapoptotic kynurenines, IDO greatly affects T-cell proliferation and survival, both in vitro and in vivo, and also affects B-cell and NK-cell function and survival. There is a central role for IDO expression in tolerance involving regulatory cells and DCs. IDO acts as an intermediate pathway in LPS-induced production of reactive oxygen species and NF-kappaB activation, two processes that lead to DC maturation. The polyclonal antibody is obtained after immunization of sheep with recombinant IDO. Reactivity of the polyclonal antibody with IDO has been confirmed on immuno blot with IFN-gamma stimulated human peripheral blood lymphocytes.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA